Clinical trial
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
NCT00427349 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00427349 |
|---|---|
| Title | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors |
| Official title | A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome |
| Intervention type | Drug |
| Interventions | AMG 706, octreotide |
| Enrollment | 46 |
| Start date | Nov 7, 2008 |
| Primary completion | Oct 1, 2014 |
| Completion | Apr 1, 2015 |
| First posted | Jan 29, 2007 |
| Last update posted | Jul 5, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: